PFE vs SIGA

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

SIGA Technologies maintains a strong, monopolistic position with TPOXX, an FDA-approved smallpox antiviral, leading to stable government contracts and robust financial health with no debt. Its leadership team has a proven track record within the biodefense sector. However, the core market of government stockpiling inherently limits the potential for exponential, 10x growth within a a 3-5 year hori...